Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axitinib + cisplatin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Axitinib + cisplatin + pemetrexed is a combination regimen of three drugs used in the treatment of certain cancers. Axitinib is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 to reduce angiogenesis. Cisplatin is a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. Pemetrexed is an antifolate chemotherapeutic agent that disrupts folate-dependent metabolic processes essential for cell replication. This combination has been studied primarily in advanced non-squamous non-small-cell lung cancer (NSCLC) and malignant pleural mesothelioma. Clinical trials have shown the regimen to be generally well tolerated but without significant improvement in progression-free or overall survival compared to standard chemotherapy alone[1][2][6].
- Other names
- axitinib + cisplatin + pemetrexed
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on axitinib + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axitinib + cisplatin + pemetrexed.